Cinrebafusp alfa
- Generic Name
- Cinrebafusp alfa
- Drug Type
- Biotech
- CAS Number
- 2218515-90-1
- Unique Ingredient Identifier
- 21Z359Z1CV
PRS-343 in HER2-Positive Solid Tumors
Phase 1
Completed
- Conditions
- HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Bladder CancerHER2-positive Solid Tumor
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Pieris Pharmaceuticals, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT03330561
- Locations
- 🇺🇸
Georgetown University, Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath